等待肝移植的肝细胞癌和胆管癌患者的治疗选择

Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma.

作者信息

Unzueta Alberto, Cabrera Roniel

机构信息

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, 1600 Southwest Archer Road, P.O. Box 100277, Gainesville, FL 32610, USA.

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, 1600 Southwest Archer Road, P.O. Box 100277, Gainesville, FL 32610, USA; Liver Transplant Program, Section of Hepatobiliary Diseases (Liver Unit), Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, 1600 Southwest Archer Road, MSB Room M440, Gainesville, FL 32610, USA.

出版信息

Clin Liver Dis. 2017 May;21(2):231-251. doi: 10.1016/j.cld.2016.12.002.

DOI:10.1016/j.cld.2016.12.002

PMID:28364811

Abstract

Liver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA). Patients with HCC on a waiting list for LT are at risk for tumor progression and dropout. Treatment of HCC with locoregional therapies may lessen dropout due to tumor progression. Strict selection and adherence to the LT criteria for patients with pCCA before and after neoadjuvant chemotherapy are critical for optimal outcome with LT. This article reviews the existing data for the various treatment strategies used for patients with HCC and pCCA awaiting LT.

摘要

肝移植（LT）为选定的肝细胞癌（HCC）和肝门周围胆管癌（pCCA）患者提供了良好的治愈机会。等待肝移植的HCC患者有肿瘤进展和退出等待名单的风险。采用局部区域治疗方法治疗HCC可能会减少因肿瘤进展导致的退出。对于pCCA患者，在新辅助化疗前后严格选择并遵守肝移植标准对于肝移植获得最佳疗效至关重要。本文综述了用于等待肝移植的HCC和pCCA患者的各种治疗策略的现有数据。